With the end of the pandemic, sales of Pfizer’s PFE COVID products, Comirnaty and Paxlovid, have declined from their peak. However, Pfizer’s non-COVID operational revenues are improving, driven by its ...

Exelixis’ EXEL year-to-date performance has been good. Shares of the biotech company have gained 15.6% compared with the ...

Exelixis(EXEL) is developing zanzalintinib— a next-generation oral investigational tyrosine kinase inhibitor (TKI) — which inhibits the activity of receptor tyrosine kinases implicated in cancer ...

During a live event, Nataliya Mar, MD, discussed systemic therapies such as lenvatinib/pembrolizumab in advanced renal cell ...